CG Oncology (CG Oncology) Long-Term Debt : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Long-Term Debt?

CG Oncology's Long-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

CG Oncology's annual Long-Term Debt declined from Dec. 2021 ($12.06 Mil) to Dec. 2022 ($6.53 Mil) and declined from Dec. 2022 ($6.53 Mil) to Dec. 2023 ($0.00 Mil).

CG Oncology Long-Term Debt Historical Data

The historical data trend for CG Oncology's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Long-Term Debt Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Long-Term Debt

12.06

6.53

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial			6.53	-	-	-	-

CG Oncology (NAS:CGON) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

CG Oncology Long-Term Debt Related Terms

Thank you for viewing the detailed overview of CG Oncology's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024